marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2022-Q2
added 08-15-2022
La Jolla Pharmaceutical Company Balance Sheet 2011-2024 | LJPC
Annual Balance Sheet La Jolla Pharmaceutical Company
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-46.4 M | -20.7 M | -58.6 M | -173 M | -90.9 M | -65.7 M | -126 M | -48.6 M | -8.63 M | -3.4 M | -5.04 M |
Long Term Debt |
164 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
154 K | 204 K | 2.77 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 148 M | 164 M | 138 M | 12.8 M | - | - | - | - | - | 5.13 M |
Total Current Liabilities |
17.6 M | 12.3 M | 24.6 M | 30.4 M | 18.6 M | 9.76 M | 4.82 M | 2.08 M | 1.09 M | 216 K | 15.5 M |
Total Liabilities |
168 M | 160 M | 188 M | 168 M | 31.3 M | 9.76 M | 4.82 M | 2.08 M | 1.09 M | 216 K | 20.7 M |
Deferred Revenue |
2.85 M | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.06 B | -1.08 B | -1.04 B | -921 M | -722 M | -607 M | -529 M | -487 M | -465 M | -447 M | -440 M |
Total Assets |
101 M | 72.2 M | 132 M | 204 M | 120 M | 70.8 M | 129 M | 50.5 M | 8.75 M | 3.43 M | 5.1 M |
Cash and Cash Equivalents |
46.7 M | 21.2 M | 87.8 M | 173 M | 90.9 M | 65.7 M | 126 M | 48.6 M | 8.63 M | 3.4 M | 5.04 M |
Book Value |
-66.7 M | -88.1 M | -56 M | 35.9 M | 88.2 M | 61 M | 125 M | 48.5 M | 7.65 M | 3.21 M | -15.6 M |
Total Shareholders Equity |
-66.7 M | -88.1 M | -56 M | 35.9 M | 88.2 M | 61 M | 125 M | 48.5 M | 7.65 M | 3.21 M | -15.6 M |
All numbers in USD currency
Quarterly Balance Sheet La Jolla Pharmaceutical Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 75 K | 120 K | 164 K | 208 K | 251 K | 294 K | 332 K | 332 K | 332 K | 332 K | 26.5 M | 26.5 M | 26.5 M | 26.5 M | 124 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | 169 M | 167 M | 168 M | 169 M | 167 M | 162 M | 160 M | 160 M | 160 M | 160 M | 188 M | 188 M | 188 M | 188 M | 168 M | 168 M | 168 M | 168 M | 31.3 M | 31.3 M | 31.3 M | 31.3 M | 9.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 2.85 M | 2.85 M | 2.85 M | 2.98 M | 3.04 M | - | 188 K | - | 188 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | -1.05 B | -1.06 B | -1.06 B | -1.06 B | -1.06 B | -1.06 B | -1.08 B | -1.08 B | -1.08 B | -1.08 B | -1.04 B | -1.04 B | -1.04 B | -1.04 B | -921 M | -921 M | -921 M | -921 M | -722 M | -722 M | -722 M | -722 M | -607 M | -607 M | -607 M | -607 M | -529 M | -529 M | -529 M | -529 M | -487 M | -487 M | -487 M | -487 M | -465 M | -465 M | -465 M | -465 M | -447 M | -447 M | -447 M | -447 M | -440 M | -440 M | -440 M | -440 M |
Total Assets |
- | - | 99.4 M | 96.4 M | 101 M | 100 M | 100 M | 89.6 M | 72.2 M | 72.2 M | 72.2 M | 72.2 M | 132 M | 132 M | 132 M | 132 M | 204 M | 204 M | 204 M | 204 M | 120 M | 120 M | 120 M | 120 M | 70.8 M | 70.8 M | 70.8 M | 70.8 M | 129 M | 129 M | 129 M | 129 M | 50.5 M | 50.5 M | 50.5 M | 50.5 M | 8.75 M | 8.75 M | 8.75 M | 8.75 M | 3.43 M | 3.43 M | 3.43 M | 3.43 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M |
Cash and Cash Equivalents |
- | - | 48.3 M | 44.2 M | 46.7 M | 46.8 M | 45.9 M | 38.6 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 87.8 M | 87.8 M | 87.8 M | 87.8 M | 173 M | 173 M | 173 M | 173 M | 90.9 M | 90.9 M | 90.9 M | 90.9 M | 65.7 M | 65.7 M | 65.7 M | 65.7 M | 126 M | 126 M | 126 M | 126 M | 48.6 M | 48.6 M | 48.6 M | 48.6 M | 8.63 M | 8.63 M | 8.63 M | 8.63 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 5.04 M | 5.04 M | 5.04 M | 5.04 M |
Book Value |
- | - | -69.5 M | -70.5 M | -66.7 M | -68.4 M | -67.4 M | -72.3 M | -88.1 M | -88.1 M | -88.1 M | -88.1 M | -56 M | -56 M | -56 M | -56 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 88.2 M | 88.2 M | 88.2 M | 88.2 M | 61 M | 70.8 M | 70.8 M | 70.8 M | 129 M | 129 M | 129 M | 129 M | 50.5 M | 50.5 M | 50.5 M | 50.5 M | 8.75 M | 8.75 M | 8.75 M | 8.75 M | 3.43 M | 3.43 M | 3.43 M | 3.43 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M |
Total Shareholders Equity |
- | - | -69.5 M | -70.5 M | -66.7 M | -68.4 M | -67.4 M | -72.3 M | -88.1 M | -88.1 M | -88.1 M | -88.1 M | -56 M | -56 M | -56 M | -56 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 88.2 M | 88.2 M | 88.2 M | 88.2 M | 61 M | 61 M | 61 M | 61 M | 125 M | 125 M | 125 M | 125 M | 48.5 M | 48.5 M | 48.5 M | 48.5 M | 7.65 M | 7.65 M | 7.65 M | 7.65 M | 3.21 M | 3.21 M | 3.21 M | 3.21 M | -15.6 M | -15.6 M | -15.6 M | -15.6 M |
All numbers in USD currency